

CORRECTION

Correction: Overexpression of *MEOX2* and *TWIST1* is Associated with H3K27me3 Levels and Determines Lung Cancer Chemoresistance and Prognosis

Federico Ávila-Moreno, Leonel Armas-López, Aldo M. Álvarez-Moran, Zoila López-Bujanda, Blanca Ortiz-Quintero, Alfredo Hidalgo-Miranda, Francisco Urrea-Ramírez, R. María Rivera-Rosales, Eugenia Vázquez-Manríquez, Erika Peña-Mirabal, José Morales-Gómez, Juan C. Vázquez-Minero, José L. Téllez-Becerra, Roberto Ramírez-Mendoza, Alejandro Ávalos-Bracho, Enrique Guzmán de Alba, Karla Vázquez-Santillán, Vilma Maldonado-Lagunas, Patricio Santillán-Doherty, Patricia Piña-Sánchez, Joaquín Zúñiga-Ramos

In [Fig 4](#), the statistical significance indicators are missing. Please see the corrected [Fig 4](#) here.



 OPEN ACCESS

Citation: Ávila-Moreno F, Armas-López L, Álvarez-Moran AM, López-Bujanda Z, Ortiz-Quintero B, Hidalgo-Miranda A, et al. (2016) Correction: Overexpression of *MEOX2* and *TWIST1* is Associated with H3K27me3 Levels and Determines Lung Cancer Chemoresistance and Prognosis. PLoS ONE 11(2): e0146569. doi:10.1371/journal.pone.0146569

Published: February 10, 2016

Copyright: © 2016 Ávila-Moreno et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Fig 4. Analysis of the enrichment profile of H3K27me3, H3K27ac and H3K4me3 at the *MEOX2* and *TWIST1* promoters in NSCLC patients. (A) H3K27me3 enrichment in the *MEOX2* promoter sequence (**Mann-Whitney U test, $p \leq 0.01$, and F test, $p \leq 0.0003$) and (B) H3K27me3 enrichment in the *TWIST1* promoter sequence in high survival patients as compared to patients with poor prognoses (**Mann-Whitney U test, $p \leq 0.01$, and unpaired t-test, $p \leq 0.02$). (C) H3K27ac enrichment in the promoter sequence of *MEOX2* (no significant changes) and (D) H3K27ac enrichment in the promoter sequence of *TWIST1* in high survival patients compared to patients with poor prognoses (no significant changes). (E) H3K4me3 enrichment in the *MEOX2* promoter

sequence (*F test, $p \leq 0.02$) and (F) the *TWIST1* promoter sequence in high survival patients compared to patients with poor prognoses (***F test, $p \leq 0.0006$). Error bars represent mean with range.

doi:10.1371/journal.pone.0146569.g001

Reference

1. Ávila-Moreno F, Armas-López L, Álvarez-Moran AM, López-Bujanda Z, Ortiz-Quintero B, Hidalgo-Miranda A, et al. (2014) Overexpression of *MEOX2* and *TWIST1* Is Associated with H3K27me3 Levels and Determines Lung Cancer Chemo-resistance and Prognosis. PLoS ONE 9(12): e114104. doi: [10.1371/journal.pone.0114104](https://doi.org/10.1371/journal.pone.0114104) PMID: [25460568](https://pubmed.ncbi.nlm.nih.gov/25460568/)